Literature DB >> 27185839

When the Minimal Becomes Measurable.

Christopher S Hourigan1, Meghali Goswami2, Minoo Battiwalla2, Austin J Barrett2, Sheenu Sheela2, Judith E Karp2, Catherine Lai2.   

Abstract

Year:  2016        PMID： 27185839     DOI： 10.1200/JCO.2016.67.6395

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  12 in total

Review 1.  Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia.

Authors:  Mary-Elizabeth Percival; Catherine Lai; Elihu Estey; Christopher S Hourigan
Journal:  Blood Rev       Date:  2017-02-02       Impact factor: 8.250

2.  MRD evaluation of AML in clinical practice: are we there yet?

Authors:  Sylvie D Freeman; Christopher S Hourigan
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 3.  Measurable residual disease testing in acute myeloid leukaemia.

Authors:  C S Hourigan; R P Gale; N J Gormley; G J Ossenkoppele; R B Walter
Journal:  Leukemia       Date:  2017-04-07       Impact factor: 11.528

4.  Measurable Residual Disease Assessment as a Surrogate Marker in New Drug Development in Acute Myeloid Leukemia.

Authors:  Gege Gui; Christopher S Hourigan
Journal:  Cancer J       Date:  2022 Jan-Feb 01       Impact factor: 3.360

5.  Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.

Authors:  Matthew P Mulé; Gabriel N Mannis; Brent L Wood; Jerald P Radich; Jimmy Hwang; Nestor R Ramos; Charalambos Andreadis; Lloyd Damon; Aaron C Logan; Thomas G Martin; Christopher S Hourigan
Journal:  Biol Blood Marrow Transplant       Date:  2016-08-17       Impact factor: 5.742

6.  Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.

Authors:  Sylvie D Freeman; Robert K Hills; Paul Virgo; Naeem Khan; Steve Couzens; Richard Dillon; Amanda Gilkes; Laura Upton; Ove Juul Nielsen; James D Cavenagh; Gail Jones; Asim Khwaja; Paul Cahalin; Ian Thomas; David Grimwade; Alan K Burnett; Nigel H Russell
Journal:  J Clin Oncol       Date:  2018-03-30       Impact factor: 44.544

Review 7.  The Prognostic Significance of Measurable ("Minimal") Residual Disease in Acute Myeloid Leukemia.

Authors:  Francesco Buccisano; Christopher S Hourigan; Roland B Walter
Journal:  Curr Hematol Malig Rep       Date:  2017-12       Impact factor: 3.952

Review 8.  Personalizing initial therapy in acute myeloid leukemia: incorporating novel agents into clinical practice.

Authors:  Christin B DeStefano; Christopher S Hourigan
Journal:  Ther Adv Hematol       Date:  2018-03-27

Review 9.  Technical Advances in the Measurement of Residual Disease in Acute Myeloid Leukemia.

Authors:  Gregory W Roloff; Catherine Lai; Christopher S Hourigan; Laura W Dillon
Journal:  J Clin Med       Date:  2017-09-19       Impact factor: 4.241

10.  Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.

Authors:  Christopher S Hourigan; Laura W Dillon; Gege Gui; Brent R Logan; Mingwei Fei; Jack Ghannam; Yuesheng Li; Abel Licon; Edwin P Alyea; Asad Bashey; H Joachim Deeg; Steven M Devine; Hugo F Fernandez; Sergio Giralt; Mehdi Hamadani; Alan Howard; Richard T Maziarz; David L Porter; Bart L Scott; Erica D Warlick; Marcelo C Pasquini; Mitchell E Horwitz
Journal:  J Clin Oncol       Date:  2019-12-20       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.